Thymosin Beta 4 Promotes Recovery of Peripheral Neuropathy in Diabetic Mice
Thymosin Beta 4 Promotes Recovery of Peripheral Neuropathy in Diabetic Mice
批准号:
8421251
负责人:
Lei Wang
金额:
$32.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-06-01 至 2017-05-31
关键词:
Acute myocardial infarctionAffectAftercareAmericanAmino AcidsAngiopoietin-2AngiopoietinsAnimalsBiological ProcessBlood VesselsBlood capillariesClinicClinical DataClinical TreatmentComplications of Diabetes MellitusDataDevelopmentDiabetes MellitusDiabetic NeuropathiesDiabetic mouseDiseaseEndothelial CellsExhibitsFunctional disorderG ActinGenesHyperglycemiaIn VitroInflammationLeadMeasuresMediatingMolecularMusMyocardial InfarctionNatural regenerationNerveNervous System PhysiologyNeuraxisNeurologic DysfunctionsNeurological outcomeNeuronsPainPatientsPeptidesPeripheralPeripheral NervesPeripheral Nervous SystemPeripheral Nervous System DiseasesPhasePhase I Clinical TrialsPublishingRecoveryRegional Blood FlowResearchRoleSchwann CellsSignal PathwaySmall Interfering RNASpinal GangliaTIE-2 ReceptorTechniquesTestingTherapeuticTherapeutic EffectThymosinTimeTissuesTranslationsTreatment EfficacyTubeangiogenesisbasecapillarydb/db mousedensitydesigndiabeticdisabilityeffective therapyimprovedin vivoinhibitor/antagonistinjuredinnovationinsightmouse modelneutralizing antibodynovelpolypeptidepre-clinicalpreclinical studypublic health relevanceresearch studysciatic nervestemthymosin beta(4)vasculogenesiswortmannin
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Peripheral neuropathy is one of the major complications of diabetes. There is a compelling need to develop effective therapeutic approaches specifically designed to improve neurological function in the damaged peripheral nervous system after diabetes. Thymosin ¿4 (T¿4), a major intracellular G-actin- sequestering peptide, has multiple biological functions, including promotion of remodeling of injured and damaged tissues, and increasing angiogenesis after myocardial infarction. However, the role of T¿4 in diabetic peripheral neuropathy has not been investigated. In a novel set of experiments, our data show that Tbeta4 remarkably improved sciatic nerve vascular function and peripheral nerve function in diabetic mice, indicating that T¿4 may have a beneficial effect on the clinical treatment of diabetic peripheral neuropathy. In this application, we therefore seek to investigate the mechanisms underlying the therapeutic effects of T¿4 on the treatment of diabetic peripheral neuropathy. We propose that T¿4 by improving vascular function ameliorates diabetic peripheral neuropathy. Our hypotheses are: 1. Treatment with Tbeta4 improves neurological function of peripheral neuropathy in diabetic mice. 2. The Ang/Tie2 signaling pathway mediates the therapeutic effect of T¿4 on neurovascular function in diabetic peripheral neuropathy. 3. The PI3K/Akt signaling pathway underlies the effect of Tbeta4 on Ang1/Ang2 expression. To investigate the effect of T¿4 on neurological outcome, type II diabetic mice which develop severe peripheral neuropathy will be treated with T¿4 at various time points after onset of diabetes. To investigate the molecular mechanisms that mediate Tbeta4-enhanced neurovascular function in diabetic mice, the effect of T¿4 on expression of Ang/Tie2 and activation of PI3K/Akt signaling pathway will be examined. Using pharmacological inhibitors and siRNA gene knockdown techniques, we will investigate the cause-effect of the Ang/Tie2 and PI3K/Akt signaling pathways on regulating T¿4-enhanced neurovascular function and axonal outgrowth. These studies are innovative and will provide new insight into mechanisms underlying the neurological dysfunction of diabetic peripheral neuropathy and lead to the development of a new treatment using T¿4. Relevance Statement: Peripheral neuropathy often stemming from diabetes is a major disability affecting millions of Americans. In this proposal, employing preclinical studies in the diabetic animal, I seek to develop a novel treatment for peripheral neuropath using T¿4. T¿4 is currently in a phase II clinic trial for the treatment of patients with acute myocardial infarction. In this proposal, I also elucidate the molecular mechanism by which T¿4 is therapeutically effective. This research will provide the essential pre-clinical data for translation to a phase 1 clinical trial.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Covalent Protein Binders for Cancer Research and Therapy
-
批准号:10360531
-
项目类别:
-
资助金额:$39.42万
-
财政年份:2021
-
负责人:Lei Wang
-
依托单位:
Covalent Protein Binders for Cancer Research and Therapy
-
批准号:10179199
-
项目类别:
-
资助金额:$40.22万
-
财政年份:2021
-
负责人:Lei Wang
-
依托单位:
Covalent Protein Binders for Cancer Research and Therapy
-
批准号:10569518
-
项目类别:
-
资助金额:$39.61万
-
财政年份:2021
-
负责人:Lei Wang
-
依托单位:
TERBO BRAIN Study: Trajectories of Emotional Regulation and Behavior Outcomes and related Brain Regions And Intrinsic Networks
-
批准号:10663934
-
项目类别:
-
资助金额:$42.12万
-
财政年份:2020
-
负责人:Lei Wang
-
依托单位:
TERBO BRAIN Study: Trajectories of Emotional Regulation and Behavior Outcomes and related Brain Regions And Intrinsic Networks
-
批准号:10065446
-
项目类别:
-
资助金额:$59.87万
-
财政年份:2020
-
负责人:Lei Wang
-
依托单位:
Schwann cell derived exosomes improve diabetic peripheral neuropathy in type II diabetic mice
-
批准号:10121320
-
项目类别:
-
资助金额:$41.12万
-
财政年份:2020
-
负责人:Lei Wang
-
依托单位:
TERBO BRAIN Study: Trajectories of Emotional Regulation and Behavior Outcomes and related Brain Regions And Intrinsic Networks
-
批准号:10264955
-
项目类别:
-
资助金额:$43.03万
-
财政年份:2020
-
负责人:Lei Wang
-
依托单位:
Schwann cell derived exosomes improve diabetic peripheral neuropathy in type II diabetic mice
-
批准号:10413254
-
项目类别:
-
资助金额:$41.12万
-
财政年份:2020
-
负责人:Lei Wang
-
依托单位:
Schwann cell derived exosomes improve diabetic peripheral neuropathy in type II diabetic mice
-
批准号:10643939
-
项目类别:
-
资助金额:$41.12万
-
财政年份:2020
-
负责人:Lei Wang
-
依托单位:
Schwann cell derived exosomes improve diabetic peripheral neuropathy in type II diabetic mice
-
批准号:10262969
-
项目类别:
-
资助金额:$41.12万
-
财政年份:2020
-
负责人:Lei Wang
-
依托单位:
Macula densa NOS1 and transplanted renal graft function
-
批准号:10609888
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2020
-
负责人:Lei Wang
-
依托单位:
Macula densa NOS1 and transplanted renal graft function
-
批准号:10380831
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2020
-
负责人:Lei Wang
-
依托单位:
Macula densa NOS1 and transplanted renal graft function
-
批准号:9973527
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2020
-
负责人:Lei Wang
-
依托单位:
Nano-switches for optogenetic control of neuronal proteins with ultra-specificity
-
批准号:9379982
-
项目类别:
-
资助金额:$175.18万
-
财政年份:2017
-
负责人:Lei Wang
-
依托单位:
Adding new covalent bonds to proteins in live cells
-
批准号:10264120
-
项目类别:
-
资助金额:$35.08万
-
财政年份:2016
-
负责人:Lei Wang
-
依托单位:
Adding new covalent bonds to proteins in live cells
-
批准号:10651718
-
项目类别:
-
资助金额:$35.08万
-
财政年份:2016
-
负责人:Lei Wang
-
依托单位:
Adding new covalent bonds to proteins in live cells
-
批准号:10119770
-
项目类别:
-
资助金额:$39.48万
-
财政年份:2016
-
负责人:Lei Wang
-
依托单位:
Adding New Covalent Bonds to Proteins in Live Cells
-
批准号:9264558
-
项目类别:
-
资助金额:$28.57万
-
财政年份:2016
-
负责人:Lei Wang
-
依托单位:
Adding new covalent bonds to proteins in live cells
-
批准号:10442720
-
项目类别:
-
资助金额:$35.08万
-
财政年份:2016
-
负责人:Lei Wang
-
依托单位:
Thymosin Beta4 Promotes the Recovery of Peripheral neuropathy in Type II Diabetic
-
批准号:8841342
-
项目类别:
-
资助金额:$32.3万
-
财政年份:2013
-
负责人:Lei Wang
-
依托单位:
海外基金